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Abstract 
Food allergy has an increasing prevalence in the general population and in Italy concerns 8 % of people with allergies. 
The spectrum of its clinical manifestations ranges from mild symptoms up to potentially fatal anaphylactic shock. A 
number of patients can be diagnosed easily by the use of first‑ and second‑level procedures (history, skin tests and 
allergen specific IgE). Patients with complex presentation, such as multiple sensitizations and pollen‑food syndromes, 
frequently require a third‑level approach including molecular diagnostics, which enables the design of a component‑
resolved sensitization profile for each patient. The use of such techniques involves specialists’ and experts’ skills on the 
issue to appropriately meet the diagnostic and therapeutic needs of patients. Particularly, educational programs for 
allergists on the use and interpretation of molecular diagnostics are needed.
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Background
Food Allergy (FA) is an increasingly recognized problem 
in relation to its prevalence in the general population. In 
Italy, it corresponds to 8  % of all patients with allergies 
[1–3] and the broad spectrum of its clinical manifesta-
tions, ranging from mild symptoms up to potentially fatal 
anaphylactic shock (Table 1). FA significantly affects the 
quality of life of patients and their families [4]. In adults, 
FA may persist from childhood or may develop at an 
older age. In the latter case, once established, FA is main-
tained throughout life, while paediatric FA frequently 
disappears during adolescence. FA may be responsible for 
signs and symptoms that occur shortly after consumption 
of the culprit food (from a few minutes to a few hours). 
The earlier they arise, the more serious they are. At times, 
symptoms appear after physical exercise (food dependent 
exercise induced anaphylaxis, FDEIA) and the ingestion 
(about 3 h before) of a specific food, which is safely eaten 
in the absence of exercise [5].
FA most commonly affects the skin (atopic dermatitis, 
urticaria, angioedema, eczema and various skin rashes) 
[6, 7]. Frequently, gastrointestinal manifestations are 
associated with cutaneous symptoms. The gut is rarely 
the only organ affected by food allergy. Symptoms range 
from dyspepsia and meteorism to colic, diarrhoea (rarely 
constipation), vomiting, gastroesophageal reflux, up to 
the most complex malabsorption syndromes, generally 
due to the infiltration of inflammatory cells in the gastro-
intestinal mucosa [8–10]. In some cases, mainly in pol-
len-allergic patients sensitive to molecules homologous 
to those contained in specific foods, symptoms appear 
in the form of itching and burning of the oral mucosa, 
papules or vesicles in the mouth, swelling of the lips and 
difficulty in swallowing, being defined as oral allergy syn-
drome [11]. Rhinitis, conjunctivitis, asthma and laryngeal 
edema are all possible FA manifestations independent 
from sensitization to inhalant allergens [12].
Each year 4–5/100,000 patients experience an anaphy-
lactic shock, with a cumulative risk equal to 0.5–2 % [13]. 
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Foods are the main cause of anaphylactic shock for chil-
dren and young adults, whereas for older people, insect 
stings are mainly responsible. This syndrome is due to the 
involvement of the cardiovascular system with a drop in 
blood pressure due to vasodilation and leakage of fluids 
from the circulation, with systemic consequences [14]. 
The term anaphylaxis (without shock) is referred to a 
reaction involving multiple organs, usually the skin, gas-
trointestinal tract and respiratory system.
There is no consensus on allergy due to food contami-
nant and additives. Clinicians sometimes report the dis-
appearance of the characteristic symptoms of food allergy 
after an additive-free diet, despite the fact that there is no 
scientific evidence on their actual role in causing symp-
toms [15–17]. In any case, reactions are not mediated by 
an immunological mechanism and are classified as non-
allergic hypersensitivity reactions. There is a possibility 
that food reactions also stem from some non-protein 
food component or from other mechanisms, for exam-
ple, cell-mediated mechanisms. These include reactions 
to orally ingested nickel, the so-called Systemic Nickel 
Allergy Syndrome, which is characterized by the appear-
ance of gastrointestinal symptoms (typically meteorism, 
colic and diarrhoea) and skin manifestations (eczema, 
urticaria and angioedema) in sites without nickel contact 
in patients with nickel contact dermatitis, and responds 
positively to a low-nickel diet [18].
Diagnostic efforts are directed to the identification of 
the food(s) involved in triggering and/or maintaining the 
symptoms. This can be achieved by using all available 
diagnostic methods applied in an appropriate sequence, 
avoiding non-standardized ones.
The purpose of this document is to define guidelines 
for the use and interpretation of scientifically validated 
and recognized diagnostic methods for food allergy.
Basic concepts of FA
Primary forms of FA are due to a sensitization process 
caused by ingestion. In the secondary forms, the patient 
is sensitized by inhalation to allergens containing mol-
ecules homologous to those contained in certain foods, 
whose ingestion may cause symptoms usually in the oral 
cavity, in the frame of an oral allergy syndrome [19]. 
Several molecules with different characteristics act as 
food allergens. Some of them are stable, enduring heat-
ing, cooking, storage and digestion (linear epitopes), 
while others are less stable (conformational epitopes) 
losing their allergenicity in cooking and preservation 
[20]. The patient with FA can be sensitized to both labile 
and stable components. The stability/lability to physical 
agents (heat, gastric pH, enzymes like protease, pepsin 
and so on) is a requisite for an allergen to interact with 
the IgE antibody. Thus, a component sensitive to heat 
will be virtually absent in a cooked food, while a deter-
minant resistant to heat, pH and peptidase (for exam-
ple, Lipid Transfer proteins–LTP) will reach the bowel 
practically intact despite cooking and passage through 
the gastric and pancreatic digestion [21]. A particular 
situation arises with the use of antacid drugs that do not 
allow (or partially allow) the denaturation of acid sensi-
tive proteins, thus resulting in unpredictable symptoms 
[22]. Other substances can act as “co-factors”, increasing 
the likelihood of anaphylaxis from food allergens. They 
include alcohol, non-steroidal anti-inflammatory drugs 
(NSAIDs), hormonal influences, bacterial or viral or par-
asitic infections [23] and chemicals [24–26].
The large variety of clinical manifestations (Table  1) 
and the complexity of allergens often make the diagnosis 
of FA difficult. A component-specific profile, other than 
extract-specific, should be used for an optimal definition 
of the sensitization. In addition, in the specific field of 
food allergy, it is crucial to discriminate between cross-
reactions and co-sensitization, particularly for mem-
bers of the plant kingdom (“pollen food allergy”), and 
to more accurately estimate the risk of severe reactions. 
The sensitization to cross-reactive molecules is relatively 
rare in childhood but tends to appear during adoles-
cence and remains stable in adults. The recent adoption 
of individual allergenic molecules (Molecular-Based 
Diagnosis, MBD) in diagnosis allows for the definition 
of a more precise IgE profile for the patient, e.g. adding 
prognostic information related to the possible risk pro-
file of the reaction. Understanding the fine relationships 
between the results of in vivo and in vitro tests and the 
Table 1 Main food allergy symptoms
Organs and systems Clinical manifestations
Respiratory Oculorhinitis
Bronchial asthma
Oedema of the glottis
Skin and subcutaneous tissue Erythematous rash
Itching without rash
Urticaria‑angioedema
Atopic dermatitis
Eczema
Gastro‑enteric Oral Allergy Syndrome
Abdominal pains
Vomiting
Diarrhoea
Cardiovascular system Hypotension
Cardiac arrest
Anaphylactic shock
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patient’s clinical picture is the key for any further clinical 
decisions.
Diagnostic methods for food allergy
A correct diagnosis of FA requires an established diag-
nostic procedure. The first step is always the patient’s his-
tory aimed at identifying the suspected relevant food(s) 
and the relationship between the ingestion of a specific 
food and the occurrence of symptoms. Then, the depend-
ence of clinical manifestations from an immune medi-
ated reaction must be assessed. This can be done by both 
in vivo and in vitro tests.
The standardized diagnostic methods are classified into 
first, second and third level.
First‑level methods
Medical history
Medical history is essential in every field of medicine 
because it allows one to obtain all the information and 
data that can help to move towards the diagnosis of a cer-
tain disease. It comprises the physiological, family (inves-
tigating all possible genetic risk factors or any family 
predisposition) and the past and current medical history. 
The latter investigates the disorder for which the patient 
consulted a doctor. In suspected FA, repeated clinical 
manifestations related to the ingestion of given meals are 
highly indicative. Medical history should be addressed to 
clarify (a) the presence or absence of similar symptoms 
in other people when they consumed the same food(s); 
(b) the ingested food(s) in the 2–4 h before the onset of 
symptoms; (c) the allergens that may contaminate food 
preparation (for example, casein, latex, ovomucoid); (d) 
the cooking and storage of food; (e) the presence of trig-
gering factors; (f ) the existence of other allergies (such as 
respiratory or skin allergy) or other diseases [27]. A cor-
rect diagnostic approach also requires a complete physi-
cal examination. When too much time has elapsed from 
the appearance of symptoms, it could be difficult to iden-
tify the offending food, in particular, if the allergen is not 
easily identifiable or “hidden”. Medical history can be re-
evaluated starting from the results of in vitro and in vivo 
tests, which could demonstrate sensitizations to foods 
that were initially not considered [28, 29].
Skin tests
Skin prick test (SPT) The SPT is a well-standardized, sim-
ple, cheap and low-risk diagnostic test. It should be the 
first step performed and both inhalant and food allergens 
should be tested. Table  2 shows a panel of food aller-
gens to be tested, supplemented, where appropriate, by 
foods chosen according to patient’s history and dietary 
diaries, and Table 3 shows the technical procedure to be 
used. The SPTs to foods have a low specificity with a low 
positive predictive value. Thus, a positive result, unless 
confirmed by the clinical data, does not allow for a defini-
tive diagnosis of FA [28–30]. In children, cut-off values 
for the SPT reaction diameter for certain food allergen 
(milk: 8 mm, egg: 7 mm, peanut: 8 mm) have been identi-
fied but are not universally acknowledged. However, oral 
food challenges were always positive (100  % specificity) 
in children with cutaneous reactions of this diameter or 
above [31, 32]. In general, SPT have an excellent sensi-
tivity with high negative predictive value (>90  %), thus 
a negative result generally rules out the possibility of an 
IgE-mediated sensitization. However, this is true only 
for foods containing stable proteins, such as casein from 
cow’s milk, egg ovomucoid, albumin and peanut vici-
lins, which are well represented in the extract. The SPT 
performed with allergenic extracts containing thermo-
labile molecules, such as pathogenesis-related-10 (PR-10) 
proteins have a low negative predictive value. For these 
allergens, the prick + prick (P + P) procedures with fresh 
foods can be useful.
The major limitations of allergen extracts for SPT are 
represented by (a) the content, because each extract is a 
heterogeneous mixture composed of major and minor 
allergenic proteins, and other biologically inactive com-
ponents such as non-allergenic proteins, glycoproteins 
and carbohydrates, (b) the production process, because 
some allergens may undergo partial degradation during 
the extraction, (c) the cross-reactions, as different biolog-
ical sources may contain cross-reactive allergens.
An in  vivo MBD approach (available in  vitro for 
many molecules, shown in Table 4) is also possible with 
extracts containing high concentrations of LTP (a gas-
tro- and thermo-stable protein from Rosaceae) and palm 
profilins (Pho d 2, an ubiquitous gastro- and heat labile 
plant protein). Their use, to complete the diagnostics 
performed with extracts from whole sources, allow for a 
Table 2 Food panel for Prick test
Egg Peach
Peanut Apple
Beta‑lactoglobulin Cod
Banana Hazelnut
Carrot Walnut
Casein Fish
Bean Pea
Wheat flour Chicken
Shrimp Tomato
Lactalbumin Rice
Pork Celery
Corn Soybeans
Almond Egg yolk
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more precise assessment of the ingestion risk of the sus-
pected food [33].
Prick +  prick (P +  P) P +  P is performed with fresh 
food, in particular vegetables, when the commercial 
extract is negative (or unavailable) but the clinical his-
tory is suggestive. When the food is solid, the technique 
involves firstly puncturing the fresh food (some allergens 
are located just under the skin of the fruit) and then the 
patient’s skin with a lancet according to the SPT standard 
procedure [34]. When the food is liquid, the technique is 
the same as in SPT.
P +  P has a good diagnostic reliability [35] with high 
predictive negative values. In the case of a positive result, 
it must be always taken into account that some foods are 
rich in histamine and lectins and can produce false posi-
tives. Obviously, the use of skin P + P with fresh food is 
not entirely risk-free and highly sensitive subjects may 
suffer systemic adverse reactions [36].
Atopy patch test (APT)
The APT is performed through the same technique used 
for common patch testing to identify the responsible 
hapten in contact dermatitis, and is aimed at assessing 
the delayed cell-mediated hypersensitivity to foods that 
may especially occur in children with atopic dermatitis or 
gastrointestinal reactions to foods. In 2010, the APT was 
considered an emerging test, like BAT and MBD [37], but 
subsequent studies did not confirm its diagnostic role to 
be as important as the other two techniques.
Second‑level methods
In vitro assays for total serum IgE (tIgE) and specific IgE (sIgE) 
to foods
Like SPT and P + P, in vitro tests only certify a sensitiza-
tion and the interpretation of results is the allergist’s task. 
Thus, measuring tIgE may be useful in grading allergy 
conditions, but only when used in combination with 
other tests. Indeed, tIgE alone has no predictive value in 
relation to the diagnosis of FA. The assay of sIgE for food 
extracts is a second-level test in the view of costs. Thus, it 
should be requested only after skin tests. However, it may 
still be exceptionally considered a first-level test in those 
conditions in which SPT cannot be performed (e.g. very 
young paediatric patients, concomitant antihistamine 
therapy or skin alterations, risk of systemic reactions). 
Importantly, an in vivo test is able to detect the biological 
effects (revealed by wheal, redness, itching, etc.) caused 
by the presence of sIgE bound to skin mast cells, while 
the serum test only detects the presence of circulating 
IgE specific to a particular allergen. It is therefore possi-
ble that the results of the two tests are different [38].
Nowadays, quantitative methods with extracts have 
levels of sensitivity (and negative predictive values) com-
parable to APT, with high specificity and positive pre-
dictive value [37]. The test is suitable to detect the IgE 
specific for a given allergen, in a quantitative way, in a 
range between 0.10 and 100 kU/L. As for the SPT reac-
tion diameter, specific IgE levels exceeding a certain 
value (“diagnostic cut-off”) showed a predictive value of 
95 % for a symptomatic allergy [32, 39] (Table 5). Thus, 
in the presence of a compatible clinical history, sIgE can 
confirm the diagnosis of FA without requiring further 
challenge tests. However, the predictive values vary from 
one study to another. The results are influenced by many 
variables such as the patient’s age, duration of food aller-
gen avoidance at the time of testing, selection of patients 
Table 3 Technical procedure for SPT
Apply one drop for each allergen extract to be tested, maintaining a minimum distance of 3 cm between drops on the volar part of the patient’s fore‑
arm (5 cm from wrist and 3 cm from the antecubital fossa)
Apply pressure, through a sterile, disposable lancet, to each single allergen, pricking to a depth of 1 mm for each drop, perpendicular to the skin’s 
surface
Hold for about 3 s with moderate pressure without moving the hand or turning to avoid bleeding
Carefully remove the allergen solution with blotting paper
 The same procedure is to be followed to test histamine (10 mg/ml) as a positive control and physiological glycerine as a negative control
Reading of the results: after 15 min from the performance of the test
Interpretation of the test: a positive result is defined by the appearance of a wheal of at least 3 mm in average diameter. Responses to histamine and 
the negative control should be carefully considered. The latter verifies that the patient does not suffer from dermographism and the former demon‑
strates a “normal response” to histamine (with no negative interference from drugs or other conditions, such as hypo‑reactivity of the skin)
Table 4 Native or recombinant molecules available for SPT
Molecule Source
Lactalbumin Cow’s milk
Beta‑lactoglobulin Cow’s milk
Casein Cow’s milk
Ovalbumin Egg white
Ovomucoid Egg white
LTP (Pru p 3) Peach
Profilin (Pho d 2) Palm tree
PR10 (Mal d 1) Apple (not available in Italy)
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and clinical disorders, and have been validated on non-
European test subjects. It is also important to stress that 
the values of specific IgE <0.10 kU/L does not exclude the 
possibility of an IgE-mediated allergic reaction and that 
the confirmation of a negative test, in the case of strong 
clinical suspicion, can only be achieved with negative 
SPTs and negative challenge tests.
In vitro MBD
Diagnostics based on allergenic extracts allow for the 
identification of the allergen source (e.g. fish, egg, milk, 
etc.) but not the molecular component to which a patient 
is sensitized, which can be studied instead through 
in  vitro MBD and therefore used to improve the result 
of a sIgE test [20]. In vitro MBD uses molecular allergens 
isolated from a given allergen source (purified or native 
allergens) or produced by recombinant DNA technol-
ogy (recombinant allergens) (Tables 6, 7). This approach 
improves the description of the IgE repertoire against 
food allergens or their molecular components and 
explains cross-reactions and their role in FA.
The MBD approach should be used to distinguish 
patients with genuine sensitization towards a food (with 
high risk of accidental ingestion) from those with co-sen-
sitization, i.e. sensitization to ubiquitous proteins present 
in pollen (which act as primary sensitizing) and also com-
mon in food (with a much lower risk of adverse reaction). 
Again, it is possible to identify patients characterized by 
sensitization to food independently by a sensitization to 
aeroallergens (primary sensitization) and patients with 
a “pollen-food syndrome”, where the first sensitization 
occurs via inhalation and the great homology between 
the allergen of the “first sensitizer” and some food aller-
gens is responsible for the patient’s symptoms presenting 
as an oral allergy syndrome [40, 41].
Identifying cross-reactions is a further benefit of MBD. 
The allergist is able to understand whether a single, a few 
closely related or several widely different food allergen 
sources should be considered in a dietary approach. The 
allergist will also be able to assess the risk of a given FA 
identifying, by in vitro MBD, patients sensitized to “rela-
tively harmless” or potentially very dangerous compo-
nents [20] that need the prescription of life-saving drugs 
such as auto-injectable adrenaline together with a strict 
allergen avoidance. The use of MBD requires allergists to 
acquire new skills.
Primarily, they need to learn the new allergen nomen-
clature [42, 43]. International classification ranks the 
allergenic source first by its scientific name, from which 
it takes the first three letters of the generic name and 
the first letter of the species (or two letters when confu-
sion is possible): e.g. apple is scientifically called “Malus 
domestica”: therefore Mal d indicates the allergen source. 
Adding a number (1, 2, 3 etc.) indicating the chronologi-
cal order of the identification allows for the classification 
any allergenic molecules: e.g. for apple the identified mol-
ecules are named Mal d 1, Mal d2, Mal d 3, and Mal d 4.
It is also important to know the molecular allergenic 
content of foods. Some molecules are specific for a given 
food, allowing the identification of the primary sensi-
tizer, others share common epitopes (antibody binding 
sites) and the same IgE can induce an immune response 
to allergenic molecules with similar structures from dif-
ferent allergen sources [33]. In the example of apple, 
Mal d 3 is an LTP molecule homologous to the LTP of 
peach, nuts, apricot, cherry, etc. and an exclusion diet 
should prohibit all these foods, but only according to the 
patient’s history [44]. Indeed, Mal d 1 is highly homolo-
gous to the birch pollen allergen Bet v 1 and characteris-
tically induces an oral allergic reaction [45].
The molecular structure and physiochemical properties 
of allergens are major determinants of their clinical rele-
vance. For example, LTPs are particularly resistant to high 
temperature and enzymatic degradation, so cooking and 
digestive processes are unable to deactivate their aller-
genic capacity. For this reason, LTP exposure through 
the gastrointestinal tract may induce sensitization in 
predisposed individuals and may trigger severe reactions 
in sensitized patients [46]. The specific patient’s sensiti-
zation profile is relevant in terms of risk assessment. In 
Table 5 Sensitivity, specificity, positive (PPV) and negative (NPV) predictive value of tests for the detection of specific IgE 
in vitro for the most common food allergens
Allergen Sensitivity (%) Specificity (%) PPV (%) VPN (%) Diagnostic cut‑off (kUA/l)
Egg 61 95 98 38 6
Milk 57 94 95 53 15
Peanut 57 100 100 36 14
Codfish 63 91 56 93 3
Soybean 44 94 73 82 30
Wheat 61 92 74 87 26
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fact, the simultaneous sensitization to peach LTP Pru p 
3, Pru p 1 and Pru p 4 in the same patient seems to exert 
a protective role in comparison with Pru p 3 sensitization 
alone, as it is associated with less severe symptoms [47]. 
Similarly, it has been recently shown that in peach-aller-
gic patients with tomato hypersensitivity, sensitization to 
rPru p3 seems to be a surrogate biochemical marker for a 
severe tomato allergy, whereas the presence of anti-rPru 
p 1 IgE may be an indicator of a mild tomato allergy [48].
Profilins are pan-allergens (present in many plant spe-
cies not botanically related) protease sensitive and less 
heat sensitive that mainly induce an oral allergy syn-
drome, while severe reactions are rare [49].
Therefore, the allergist approaching the MBD should 
know the chemical, physical and immunological char-
acteristics of all allergenic families, their biodegradabil-
ity, cooking/heat resistance/sensibility etc. The stability/
lability of a molecule (along with the clinical history) 
helps the clinician to evaluate the risk of systemic versus 
local reactions. Stable allergens are generally associated 
with severe systemic reactions, whereas labile allergens 
are associated with low/mild reactions and cooked food 
is often tolerated.
Moreover, it is essential to know to which family the 
various molecules belong and their structural similarity 
within the family (generally characterized by a greater 
than 50–70 % sequence homology).
In the above-mentioned example of apple, MBD can 
distinguish between fruit allergy due to LTP sensitiza-
tion and a pollen-related apple allergy. Sensitization 
to Mal d 3 (an LTP protein) indicates a fruit allergy 
where peach is often the primary sensitizer [50, 51]. 
Sensitization to Mal d 1 (a PR-10 protein) is seen in 
birch-pollen allergic patients and is caused by cross-
reactivity with the main birch allergen Bet v 1 [52, 53]. 
The presence of IgE antibodies to profilin (e.g. Mal d 
4, homologous of Phl p 12) is indicative of an apple 
allergy related to a grass-pollen sensitization [53, 54]. 
Table 6 Major food allergens and  components available for  molecular diagnostics using ImmunoCAP (or ImmunoCAP 
ISAC)
Allergens (or allergen source) Protein family
Cupin superfamily
 Vicilins Ara h 1 (peanut)
 Legumins Ara h 3 (peanut), Cor 9 (hazelnut)
Prolamin superfamily
 2S albumin Ber e 1 (brazil nut), Ara h 2 (peanut), Gly m 6
 Lipid transfer protein (LTP) Pru p 3 (peach), Cor 8 (hazelnut), Art v 3 (Composite) Jug r 3 (walnut)
 Cereal prolamines Tri 19 (wheat) Tri a 14
Pathogenesis‑related (PR) proteins
 PR10: intracellular proteins Pru p 1 (peach), Api g 1 (celery), Gly m 4 (soy)
 PR3: chitinase Class 1 Hev b 11, Hev b 2.6 (latex, banana, avocado)
 Profilins Pru p 4 (peach) (Bet v 2, Phl p 12, Hev b 8)
 Cross‑reactive carbohydrate determinants MUXF3 (celery, tomato)
 Tropomyosins Pen a 1 (shrimp)
Calcium binding proteins
 Parvalbumin Gad c 1 (codfish)
 Milk proteins Bos d 4 (α‑albumin), Bos d 5 (β‑lactoglobulin), Bos d 8 (casein), Bos d lactoferrin (lactoferrin)
 Egg protein Gal d 1 (ovomucoide)
Gal d 2 (ovalbumin)
Gal d 3 (conalbumin)
Gal d 4 (lysozyme)
Table 7 Families of  protein carbohydrate molecules 
mainly involved in food allergy
Molecules associated with allergy to food source (or source allergen)
 PR‑10 proteins (homologous to Bet v 1)
 Non‑specific lipid transfer proteins (nsLTP)
 Profilins
 Storage proteins
 Thaumatin‑like‑proteins (TLP)
 Cross‑reactive carbohydrate determinants (CCD)
Molecules associated with allergy to food of animal origin
 Tropomyosins
 Parvalbumins
 Caseins
 Lipocalin, Family of lysozyme, Family Transferrins, Ovomucoids
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Patients with IgE antibodies to Mal d 2 and 3 (LTP sta-
ble proteins) are at higher risk of developing systemic 
reactions. IgE antibodies to Mal d 1 and/or profilin and 
not to Mal d 2 and 3 suggest that predominantly local 
oral symptoms may occur. Apple-allergic patients sen-
sitized to Mal d 3 may tolerate peeled apples. Apple-
allergic patients sensitized to Mal d 1 and/or profilin 
(that are labile proteins) may often tolerate cooked 
apples.
MBD is a complex area, but as it provides new and rel-
evant information for the allergist, it will soon become a 
standard tool for the diagnosis of FA. Educational pro-
grams for allergists on the use and interpretation of MBD 
are needed [55].
In vitro MBD is defined as single or multi-plexed IgE 
assay microarray. By the single-plexed diagnostics the 
choice of the components to be tested is relies on the 
allergist’s judgment, based on the patient’s sIgE pro-
file. In poly-sensitized patients, a complete recogni-
tion of the IgE profile might require a large number of 
assays. In these cases, it may be reasonable to use the 
multi-plexed allergen microarray (AMA) that allows for 
the detection of specific reactivity to over 100 allergen 
components. The most popular form (the Immuno-
Sorbent Allergen Chip—ISAC) currently contains inhal-
ants, foods, latex and insect venom. Despite AMA not 
being a quantitative assay, the correlation between the 
results of microarrays and the results of sIgE tests are 
largely super-imposable. Thus AMA is suitable in both 
paediatric and adult serum samples when the number of 
molecular components to be tested using single-plexed 
methods is too high to be cost-convenient or when the 
need for extensive research of sensitization is required 
[20]. This is particularly true in highly complex patients 
presenting symptoms of a cross-sensitization to inhal-
ant and food and clinical evidence of food allergy. AMA 
is a powerful in vitro test that requires specific expertise 
but provides a very large amount of information to the 
allergist.
MBD diagnostics, especially microarray, are expensive 
compared with traditional tests, unless a single test is 
considered. Economic considerations may influence the 
decision of using a single or multiplex approach in indi-
vidual patients. Using the microarray diagnostics allows 
for the performance of a broad-spectrum analysis of a 
patient’s IgE profile with a small blood sample. It may 
reveal unanticipated sensitivities, possibly to potentially 
harmful molecules, making the interpretation of such 
sensitization difficult in the case of a clinically silent his-
tory, but giving the allergist the chance to investigate 
other hypersensitivities and to alert the patient towards 
possible risks. This clearly demonstrates that in  vitro 
diagnostics, including MB, should be evaluated within 
the framework of a patient’s clinical history, since aller-
gen sensitization does not necessarily imply clinical 
responsiveness.
Third‑level methods
Oral provocation test (OPT)
OPTs are the most reliable tests in the diagnosis of clini-
cally relevant IgE associated food allergies once allergen 
specific IgE has been detected. The OPT remains the 
“gold standard” to establish or exclude the liability of a 
particular food in causing an adverse reaction [56–61]. 
The actual value of this method is its functional result. 
Indeed, only foods causing a clinical evidence of allergy 
are considered positive. When first and second-level 
methods have been unable to indicate the food that is 
responsible for the symptoms, the clinical relevance of a 
detected sensitization may also be investigated by a tar-
geted elimination diet to perform before the OPT [28]. 
Furthermore, if multiple triggers are suspected, the elimi-
nation diet can help in selecting food to be tested through 
the OPT, which remains the most important diagnostic 
tool in food allergy diagnosis. Once the diagnostic work-
up has been concluded, the elimination diet of the culprit 
food/s usually represents the treatment for known food 
allergies, as well as educating the patient about proper 
food preparations and the risks of occult exposure [28, 
29]. Ongoing investigations are currently evaluating the 
role of food immunotherapy as a potential FA therapy, to 
be performed by highly skilled specialists in appropriate 
settings [29, 62].
The OPT is a third-level procedure that should be car-
ried out when previous diagnostic levels were unable to 
give sufficient information for the clinical diagnosis [60]. 
During the patient follow-up, OPT is useful in detecting 
an acquired tolerance for the specific food. The functional 
identification of the causative food allows one to avoid its 
assumption as well as the establishment of unnecessary 
rigid diets. Due to the potential risk of severe adverse 
events, the test has to be performed in a hospital setting 
with personnel trained in resuscitation procedures and 
the availability of emergency drugs.
The indications of OPT [61, 63–65] are: (a) to identify 
the food responsible for acute reactions, or to monitor 
the unexpected tolerance in case of a history of allergy; 
(b) to determine the offending food in chronic condi-
tions such as atopic dermatitis or eosinophilic esophagi-
tis; (c) to expand the diet in subjects with multiple dietary 
restrictions; (d) to establish the degree of tolerance to 
cross-reactive foods and to establish possible acquisition 
of a spontaneous tolerance to food.
The contraindications are: (a) previous severe anaphy-
lactic reactions (especially recent); (b) level of specific IgE 
exceeding the cut-off for which there is a high probability 
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that the oral test is positive; (c) reactivity to individual 
molecules identified with the MBD that indicate a pos-
sible severe reaction; (d) reactions occurred during the 
performance of the SPT and (e) a progressive systemic 
disease, in particular when the patient is taking medica-
tions that could mitigate (antihistamines, corticosteroids) 
or amplify (β-blockers, ACE inhibitors, NSAIDs, etc.) the 
reaction [63, 64].
The test consists of gradually increasing doses of the 
appropriately diluted food, starting from the lowest dose 
and checking the presence of relevant symptoms. The 
test can be performed in three different settings [63]:
Open OPT is used for immediate reactions when the 
risk of severe reaction is reduced. It can be performed on 
an outpatient basis with a simplified protocol of admin-
istration and an observation time of about 2 h. It can be 
strongly influenced by the age and by the subject’s psy-
chological behaviour. If negative, the food can be rein-
troduced into the diet. In the case of suspected positive 
reaction, it should be checked in a double-blind OPT 
setting.
Single-blind placebo OPT (SBP-OPT) it consists of 
two sessions, one with placebo and one with the sus-
pected food. When a strong psychological component 
is suspected, the placebo should be tested first. The 
patient undergoing the SPB-OPT is informed that the 
food may or may not be present in the administered 
dose. If the answer is negative or positive symptoms are 
observed, it is not necessary to continue the investiga-
tion. Repeated sessions with placebo or suspected food 
are useful for the confirmation of vague symptoms. In 
the case of positivity with placebo, a DBP-OPT will be 
necessary. In the case of a negative result, the tolerated 
food must be ingested in its natural form 2 h after or on 
the day after the test. The tolerance should be checked 
with follow-up.
Double–blind placebo controlled test (DBPCT) the gold 
standard. The foods to be tested are prepared by profes-
sional personnel not involved in the clinical examina-
tion. Placebo and food must have a very similar look and 
taste. Only when the test is completed can the doctor and 
patient know the pattern of administration and discuss 
the results [66].
Fourth‑level methods
Basophil activation test (BAT)
The BAT can be used in the study of IgE (and non-IgE) 
mediated allergic reactions [67, 68]. The rationale of this 
test is the change in the phenotype of activated baso-
phils after in vitro incubation of the patient’s whole blood 
with the allergen. The BAT is a useful complementary 
tool to the in vitro diagnosis of FA caused by milk, egg, 
peanut and wheat [69, 70] when IgE may be involved. 
Interestingly, a recent study of 20 peanut-allergic chil-
dren showed that when basophils were stimulated with 
decreasing doses of allergens until threshold sensitiv-
ity was reached, 19 were negative to peanut but 17 were 
positive to rAra h 8, suggesting that the children sensi-
tized to Ara h 8 but not peanut storage proteins may be at 
risk of systemic allergic reactions, especially when eating 
large amounts of peanuts [70].
Reactions unrelated to IgE may also be assessed by 
BAT, as evidenced for wine and beef [71, 72]. Recently 
it was also used in the decision-making process for the 
reintroduction of milk in children allergic to casein [73]. 
Today, BAT is the only assay that mimics, in the test 
tube, what happens in  vivo. After an extensive valida-
tion, BAT should distinguish sensitization from a clinical 
allergy. The method still suffers some critical issues that 
can make it a routine test only in specialized laboratories 
(Fig. 1).
Complementary alternative tests
Frequently, patients undergo complementary/alternative 
tests after a negative response to a common diagnostic 
work-up or when non specific symptoms predominate 
(e.g. migraine, abdominal discomfort, chronic urticaria 
or other skin abnormalities, chronic fatigue, weight gain 
or lack of success in weight loss diets), which are erro-
neously classified as “food allergy” [74]. It represents a 
common diagnostic label suggested by physicians with-
out specific expertise in the field of FA mechanisms and 
food-related disorders [75, 76].
The most common (not validated) alternative diagnos-
tic techniques are:
In vivo:
 – Electrodermal tests: they measure the change in the 
skin’s electrical conductance once the subject has been 
exposed to an allergenic substance through specific 
devices [75].
  – Kinesiology: it registers the decreased strength of mus-
cular contraction related to contact with an allergen 
[75].
 – Provocation/neutralization testing: it identifies the 
onset of “untoward effects” provoked by the adminis-
tration (intradermal or sublingual) of allergenic sub-
stances [76]. The same technique is used as a therapeu-
tic tool.
In vitro:
  – Leukocytotoxic tests: they detect the shape/volume 
abnormalities of peripheral leukocytes when an aller-
gen in a solid and not measurable phase comes into 
contact with them [77].
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Fig. 1 Flow chart for the diagnosis of food allergy
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A direct comparison between such tests and gold 
standard methods has so far failed in all cases to demon-
strate their validity [78]. Their use is strongly discouraged.
Conclusion
The diagnosis of FA is an integrated procedure that can 
be carried out in different steps (Fig.  1). Some patients 
can be diagnosed easily by the use of first- and second-
level tests, while complex patients, with poly-sensiti-
zation and pollen-food syndromes, frequently require 
a third-level approach. In recent years, the diagnos-
tic assays for FA have been significantly expanded and 
standardized tools and procedures are now available to 
the allergist.
Currently, demanding issues are related to FA diagno-
sis: (1) Identified food(s) should be excluded from the 
diet; (2) the patient must be properly informed about 
the relative risk of ingesting the sensitizing foods, even 
inadvertently as hidden foods in different preparations; 
(3) the allergist should explain all preventive and cura-
tive measures to be taken in case of allergic reactions, 
including potential medical urgency. In particular, the 
patient must be informed of the possibility that certain 
concurrent conditions could favour the onset of FA. This 
involves a great deal of renewed research specialists and 
experts on the subject to be able to respond appropriately 
to the diagnostic and therapeutic needs of patients.
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